Beijing Luzhu Biotechnology Co., Ltd. (02480.HK) Latest Company News

Oct 12, 2026, 11:01 UTC
China's National Medical Products Administration approved Beijing Lüzhu Biotechnology Co., Ltd.'s recombinant RSV vaccine candidate for clinical trials in China.
Source:
- finance.sina.cn
- aastocks.com
Aug 9, 2026, 11:41 UTC
Green Bamboo Biotech announced that the Phase III clinical trial results of its core product LZ901 vaccine in China were published in Nature Communications on August 7, 2026, showing high protective efficacy and good safety in preventing herpes zoster in adults aged 40 and above.
Source:
- aastocks.com

02480.HK